Neurocrine Biosciences, Inc. (NASDAQ: NBIX) on Friday, plunged -0.91% from the previous trading day, before settling in for the closing price of $136.66. Within the past 52 weeks, NBIX’s price has moved between $89.20 and $148.37.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 34.77% over the past five years. The company achieved an average annual earnings per share of 88.24%. With a float of $98.39 million, this company’s outstanding shares have now reached $98.70 million.
Let’s look at the performance matrix of the company that is accounted for 1400 employees.
Neurocrine Biosciences, Inc. (NBIX) Insider Updates
Observing investor behavior towards Drug Manufacturers – Specialty & Generic industry stocks is more important than anything else. The insider ownership of Neurocrine Biosciences, Inc. is 2.24%, while institutional ownership is 93.46%. The most recent insider transaction that took place on May 29 ’24, was worth 5,338,564. In this transaction Director of this company sold 40,000 shares at a rate of $133.46, taking the stock ownership to the 26,504 shares. Before that another transaction happened on May 17 ’24, when Company’s Director sold 2,100 for $141.84, making the entire transaction worth $297,860. This insider now owns 31,611 shares in total.
Neurocrine Biosciences, Inc. (NBIX) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around 88.24% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 18.00% during the next five years compared to 62.04% growth over the previous five years of trading.
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) Trading Performance Indicators
Neurocrine Biosciences, Inc. (NBIX) is currently performing well based on its current performance indicators. A quick ratio of 2.47 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 6.88. Likewise, its price to free cash flow for the trailing twelve months is 22.18.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 3.64, a number that is poised to hit 1.15 in the next quarter and is forecasted to reach 6.96 in one year’s time.
Technical Analysis of Neurocrine Biosciences, Inc. (NBIX)
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) saw its 5-day average volume 0.95 million, a positive change from its year-to-date volume of 0.83 million. As of the previous 9 days, the stock’s Stochastic %D was 26.39%. Additionally, its Average True Range was 4.09.
During the past 100 days, Neurocrine Biosciences, Inc.’s (NBIX) raw stochastic average was set at 36.38%, which indicates a significant increase from 25.29% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 24.69% in the past 14 days, which was lower than the 25.63% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $138.43, while its 200-day Moving Average is $126.01. Nevertheless, the first resistance level for the watch stands at $137.26 in the near term. At $139.12, the stock is likely to face the second major resistance level. The third major resistance level sits at $140.96. If the price goes on to break the first support level at $133.56, it is likely to go to the next support level at $131.72. Assuming the price breaks the second support level, the third support level stands at $129.86.
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) Key Stats
Market capitalization of the company is 13.63 billion based on 100,637K outstanding shares. Right now, sales total 1,887 M and income totals 249,700 K. The company made 515,300 K in profit during its latest quarter, and 43,400 K in sales during its previous quarter.
